natgillin/translations-raw huggingface dataset:
decreased number of all blood cell types; severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke’s oedema [swelling of the face, lips, tongue and throat]);
manjen broj svih vrsta krvnih stanica; teške alergijske reakcije (DRESS, anafilaktička reakcija [teška i ozbiljna alergijska reakcija], Quinckeov edem [angioedem oticanje lica, usana, jezika i grla]);
decreased number of all blood cell types; severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke’s oedema [swelling of the face, lips, tongue and throat]);
manjen broj svih vrsta krvnih stanica; teške alergijske reakcije (DRESS, anafilaktička reakcija [teška i važna alergijska reakcija], Quinckeov edem [oticanje lica, usana, jezika i grla]);
decreased number of all blood cell types; severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke’s oedema [swelling of the face, lips, tongue and throat]);
manjen broj svih vrsta krvnih stanica; tjelesne težine alergijske reakcije (DRESS, anafilaktička reakcija [teška i ozbiljna alergijska reakcija], angioedem [oticanje lica, usana, jezika i grla];
decreased number of blood platelets (symptoms include: increased tendency to bleed or bruise)
manjeni broj trombocita (simptomi uključuju: povećanu sklonost krvarenju i nastajanju modrica)
decreased number of blood platelets, decreased number of white blood cells
manjen broj krvnih pločica, smanjen broj bijelih krvnih stanica
decreased number of blood platelets, decreased number of white blood cells;
manjen broj krvnih pločica, smanjen broj bijelih krvnih stanica;
decreased number of blood platelets, white and red blood cells (thrombocytopenia, leukocytopenia, neutropenia, anaemia )*
manjenje broja trombocita, leukocita i eritrocita (trombocitopenija, leukocitopenija, neutropenija, anemija)
decreased number of cells in the blood, including white cells that help to fight against infections (this may be accompanied by fever), and cells that help the blood to clot,
manjen broj krvnih stanica, uključujući bijele krvne stanice koje pomažu u borbi protiv infekcije (može biti praćeno vrućicom) i stanice koje pomažu u zgrušavanju krvi,
decreased number of or difficulty making bowel movements,
rjeđe ili otežano pražnjenje crijeva,
Decreased number of red blood cells (anaemia),
manjen broj crvenih krvnih stanica (anemija),
decreased number of red blood cells (anaemia), white blood cells and platelets
manjen broj crvenih krvnih stanica (anemija), bijelih krvnih stanica i trombocita
decreased number of red blood cells (symptoms include: weakness, dizziness, fatigue)
manjeni broj crvenih krvnih stanica (simptomi uključuju: slabost, omaglicu, umor)
decreased number of red cells in the blood,
manjen broj crvenih krvnih stanica,
decreased number of white blood cells
manjen broj bijelih krvnih stanica
decreased number of white blood cells (granulocytopenia)
manjeni broj bijelih krvnih stanica (granulocitopenija)
decreased number of white blood cells (neutropenia)
manjeni broj bijelih krvnih stanica (neutropenija)
decreased number of white blood cells called neutrophilis (symptoms include: increase tendency of infection)
manjeni broj bijelih krvnih stanica zvanih neutrofili (simptomi uključuju: povećanu sklonost infekcijama)
decreased numbers of red blood cells (anaemia)
manjen broj crvenih krvnih stanica (anemija)
decreased numbers of red blood cells (anaemia)
manjenjenje broja crvenih krvnih stanica (anemija)
decreased numbers of red blood cells or platelets
manjenje broja crvenih krvnih stanica ili krvnih pločica
decreased numbers of red blood cells or platelets
manjenjenje broja crvenih krvnih stanica ili krvnih pločica
decreased numbers of white blood cells (granulocytopenia)
manjeni broj bijelih krvnih stanica (granulocitopenija)
decreased numbers of white blood cells (granulocytopenia)
manjenje broja bijelih krvnih stanica (granulocitopenija)
decreased or abnormal skin sensibility, pins and needles, attention disturbance, loss of memory, problems with your balance
manjena ili nenormalna osjetljivost kože, mravci i trnci, poremećaj pažnje, gubitak pamćenja, problemi s ravnotežom
decreased or increased appetite
manjen ili povećan apetit
decreased or increased appetite, distortion of the senses of taste and smell
manjen ili povećan apetit, promjena osjeta okusa i mirisa
decreased or increased appetite, not wanting to eat some foods
manjeni ili povećani apetit, odbojnost prema određenoj vrsti hrane
decreased or increased blood levels of the hormone prolactin
nižene ili povišene razine hormona prolaktina u krvi
Decreased or increased blood pressure
niženi ili povišeni krvni tlak
Decreased or increased skin sensitivity.
Smanjena ili povećana osjetljivost kože.
Decreased or lack of reflexes, involuntary movements, pain along a nerve, fainting, dizziness when standing up, shaking, facial nerve paralysis
manjeni ili odsutni refleksi, nevoljni pokreti, bol uzduž živca, nesvjestica, omaglica prilikom ustajanja, tresavica, paraliza živca na licu
decreased oxygen in parts of your body (because of decreased blood flow), flushing
manjenje kisika u dijelovima tijela (zbog smanjenja protoka krvi), crvenilo uz osjećaj vrućine
decreased phosphate in your blood increased levels of creatine kinase in the blood that may result in muscle pain and weakness
niženu razinu fosfata u krvi povišene razine kreatin kinaze u krvi, što može rezultirati mišićnim bolovima i slabošću.
Decreased phosphorus in the blood, fluid retention, low albumin in the blood, increased thirst, decreased calcium in the blood, decreased sugar in the blood, decreased sodium in the blood
nižena razina fosfora u krvi, zadržavanje tekućine, niska razina albumina u krvi, pojačana žeđ, snižena razina kalcija u krvi, snižen šećer u krvi, snižena razina natrija u krvi
Decreased plasma concentrations of simeprevir are expected.
Očekuju se snižene koncentracije simeprevira u plazmi.
Decreased platelet count
manjen broj trombocita
Decreased platelet count (reduction of the number of platelets in the blood)
Smanjen broj trombocita (smanjenje broja trombocita u krvi)
Decreased platelet count, decreased lymphocyte count, decreased white blood cell count, decreased neutrophil count, increased aspartate aminotransferase, increased alanine aminotransferase
manjen broj trombocita, smanjen broj limfocita, smanjen broj bijelih krvnih stanica, smanjen broj neutrofila, povišena aspartat aminotransferaza, povišena alanin aminotransferaza
Decreased platelets
nižene vrijednosti trombocita
Decreased platelets in the blood, increased or decreased white cells in the blood, tendency to bleed.
manjen broj krvnih pločica u krvi, povećan ili smanjen broj bijelih krvnih stanica u krvi, sklonost krvarenju.
Decreased potassium
snižene vrijednosti kalija
decreased potassium in the blood (hypokalaemia); decreased magnesium in the blood (hypomagnesaemia); decreased calcium in the blood (hypocalcaemia)
niženi kalij u krvi (hipokalemija), sniženi magnezij u krvi (hipomagnezemija), sniženi kalcij u krvi (hipokalcemija)
decreased potassium, hypomagnesemia, increased glucose, decreased phosphorus, and increased phosphorus
snižene vrijednosti kalija, hipomagnezemija, povišene vrijednosti glukoze, snižene vrijednosti fosfora i povišene vrijednosti fosfora
decreased pressure inside the eye
nižen tlak u unutrašnjosti oka
Decreased prothrombin and increased INR (see sections 4.3 and 4.5)
Snižena vrijednost protrombina i povišen INR (vidjeti odjeljak 4.3 i 4.5)
Decreased R-warfarin levels may lead to reduced anticoagulation, therefore it is recommended that anticoagulation parameters are monitored when warfarin is co- administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
Zbog sniženih razina R-varfarina može oslabiti antikoagulacijski učinak te se stoga preporučuje praćenje koagulacijskih parametara kada se varfarin daje istodobno s ritonavirom doziranim kao antiretrovirusnim lijekom ili kao farmakokinetičkim pojačivačem.
decreased red blood cells (shown in a blood test)
manjen broj crvenih krvnih stanica (vidljivo iz nalaza krvnih pretraga)
Decreased renal function in elderly patients is frequent and asymptomatic.
U starijih bolesnika smanjena funkcija bubrega je česta i asimptomatska.
Decreased renal function in older subjects is frequent and asymptomatic.
Smanjena funkcija bubrega u starijih bolesnika je česta i asimptomatska.
Decreased renal function may lead to decreased rate of elimination and prolonged systemic exposure.
Oslabljena funkcija bubrega može dovesti do smanjenja brzine eliminacije i produljenog sistemskog izlaganja.
Decreased score (Improvement)
Smanjeni rezultat (poboljšanje)
Decreased secretion of hormones produced by adrenal glands (glands situated above the kidneys), underactive function (hypopituitarism) or inflammation (hypophysitis) of the pituitary gland situated at the base of the brain, swelling of the thyroid gland, acid in the blood produced from diabetes (diabetic ketoacidosis)
manjeno lučenje hormona koje proizvode nadbubrežne žlijezde (žlijezde smještene iznad bubrega), nedovoljna aktivnost (hipopituitarizam) ili upala (hipofizitis) hipofize, žlijezde koja se nalazi na bazi mozga, oticanje štitnjače, kiselina u krvi kao posljedica šećerne bolesti (dijabetička ketoacidoza)
Decreased secretion of hormones produced by adrenal glands (glands situated above the kidneys); underactive function (hypopituitarism) or inflammation (hypophysitis) of the pituitary gland situated at the base of the brain; overactive thyroid gland, which can cause rapid heart rate, sweating and weight loss; inflammation of the thyroid gland; swelling of the thyroid gland, high sugar levels in the blood (hyperglycaemia)
manjeno lučenje hormona koje proizvode nadbubrežne žlijezde (žlijezde smještene iznad bubrega); nedovoljna aktivnost (hipopituitarizam) ili upala (hipofizitis) hipofize, žlijezde koja se nalazi na bazi mozga; pojačana aktivnost štitnjače, koja može uzrokovati ubrzan puls, znojenje i gubitak tjelesne težine; upala štitnjače; oticanje štitnjače; visoke razine šećera u krvi (hiperglikemija)
decreased sensation
manjen osjet
Decreased sensation of your eye surface; double vision; drooping eyelid; separation of one of the layers within the eyeball after surgery to reduce the pressure in the eye; inflammation of the surface of the eye
Smanjena osjetljivost površine oka; dvoslike; spušten kapak; odvajanje jednog od slojeva unutar očne jabučice nakon kirurškog zahvata radi smanjivanja očnog tlaka; upala površine oka
decreased sensation, numbness and tingling in fingers and palm of the hand due to squeezed nerve at wrist (carpal tunnel syndrome)
manjen osjet, utrnulost i trnci u prstima i dlanovima zbog pritisnutog živca u zapešću (sindrom karpalnog kanala)
decreased sense of smell
umanjen osjet mirisa
decreased sense of taste
manjenje osjeta okusa
Decreased sense of touch like burning, tingling or feeling of numbness in your hands, arms, legs, or feet (hypoaesthesia), excessive sweating (hyperhidrosis), itching, chest pain, chills, fever (pyrexia).
Oslabljen osjet dodira kao osjećaj pečenja, žarenja ili utrnulosti u šakama, rukama, nogama ili stopalima (hipoestezija), prekomjerno znojenje (hiperhidroza), svrbež, bolovi u prsima, zimica, vrućica (pireksija).
decreased sensitivity to pain
manjena osjetljivost na bol
Decreased sensitivity to touch
manjen osjet dodira
Decreased sensitivity, especially in the skin
manjena osjetljivost, osobito kože
decreased sex drive
manjena spolna želja
decreased sexual desire;
manjena seksualna želja;
decreased sexual drive
manjen spolni nagon
Decreased sexual drive
manjeni spolni nagon
decreased sharpness of vision
manjenje oštrine vida
decreased skin sensitivity
manjena osjetljivost kože
decreased sodium in the blood (hyponatraemia); increased potassium in the blood (hyperkalaemia); decreased phosphates in the blood (hypophosphataemia); anorexia (eating disorder)
niženi natrij u krvi (hiponatremija), povišen kalij u krvi (hiperkalemija), sniženi fosfati u krvi (hipofosfatemija), anoreksija (poremećaj prehrane)
decreased solubility of atazanavir
manjena topljivost atazanavira
decreased sperm cell count
manjen broj spermija
Decreased stool production and some temporary weight loss.
Smanjenu proizvodnju stolice i određeni privremeni gubitak težine.
decreased sweating, overheating
manjeno znojenje, pregrijanost
Decreased testicular weights and hypospermia were present in rats after repeat doses
Smanjena težina testisa i hipospermija bile su prisutne u štakora nakon ponovljenih doza
decreased testosterone (sex hormone) in blood tests in females
niženje testosterona (spolnog hormona) u krvnim pretragama u žena
decreased thyroid gland activity which can cause tiredness or weight gain
manjena aktivnost štitnjače koja može uzrokovati umor ili dobivanje na tjelesnoj težini
decreased to 150 mg twice daily
Doza lijeka CELSENTRI se mora smanjiti na 150 mg dva puta
Decreased tolerability of the eyes for bright light
manjena podnošljivost očiju za jarko svjetlo
decreased uric acid in blood tests
niženje mokraćne kiseline u testovima krvi
decreased urinary output
manjeno izlučivanje mokraće
Decreased urination (problems with your kidneys),
manjeno mokrenje (tegobe s bubrezima),
decreased urine output trouble breathing
ako manje mokrite, ako otežano dišete.
decreased vision
oslabljen vid
decreased vision in parts of the field of view
labiji vid u dijelovima vidnog polja
decreased weight
manjenje tjelesne težine
Decreased weight
Smanjena težina
decreased weight mouth ulcers and cold sores (stomatitis)
manjenje tjelesne težine vrijedovi u ustima i herpes (stomatitis)
decreased white blood cell count decreased haemoglobin decreased platelet count
nižen broj bijelih krvnih stanica snižen hemoglobin snižen broj trombocita
Decreased white blood cell counts (WBC) ≤ 0.8 x lower limit of normal (LLN) were reported in 6.7% of patients treated with Ilaris compared to 1.4% treated with triamcinolone acetonide.
Smanjene razine leukocita (Lkc) ≤0,8 x donje granice normale (DGN) zabilježeno je kod 6,7% bolesnika liječenih Ilarisom u usporedbi s 1,4% liječenih triamcinolon acetonidom.
decreased white blood cells (shown in a blood test)
manjen broj bijelih krvnih stanica (u nalazima krvnih pretraga)
decreased, haematocrit decreased, white blood cell count decreased
nižen hemoglobin, snižen hematokrit, smanjeni broj leukocita
decreased, which may reduce the efficacy
može oslabiti djelotvornost
Decreases <LLN* (<90 ml/min)
smanjen <DGN-a* (<90 ml/min)
Decreases in absolute counts and percentages of total NK cells (CD16+CD56+) and activated (CD16+CD56dim) NK cells in peripheral whole blood and bone marrow were observed with daratumumab treatment.
Kod liječenja daratumumabom primijećeno je smanjenje apsolutnog broja i postotka ukupnog broja NK stanica (CD16+CD56+) i aktiviranih (CD16+CD56dim) NK stanica u perifernoj punoj krvi i koštanoj srži.
Decreases in absolute neutrophil counts (ANC) to less than 1 x 109/l were reported in 2% of patients in the comparative trials.
Smanjenje apsolutnog broja neutrofila (ABN) na manje od 1 x 109/l zabilježeno je u 2% bolesnika u komparativnim ispitivanjima.
decreases in blood cells including platelets, thinning of blood (seen in tests)
manjen broj krvnih stanica, uključujući krvne pločice, razrjeđivanje krvi (vidi se iz nalaza krvnih pretraga)
decreases in blood cells including platelets, thinning of blood (seen in tests)
manjeni broj određenih krvnih stanica, uključujući i trombocita, razrjeđivanje krvi (otkriva se krvnim pretragama)
decreases in blood cells including platelets, thinning of blood (seen in tests)
manjenje broja krvnih stanica, uključujući trombocite, razrjeđivanje krvi (vidjlivo u nalazima)
Decreases in blood glucose, in some cases clinically symptomatic and requiring hospitalization due to loss of consciousness, have been reported during sunitinib treatment.
Sniženje razine glukoze u krvi, koje je u nekim slučajevima bilo klinički simptomatsko i zahtijevalo hospitalizaciju uslijed gubitka svijesti, prijavljeno je tijekom liječenja sunitinibom.
Decreases in BMD of hip were significantly greater in this group until 96 weeks.
Smanjenja mineralne gustoće kostiju kuka bila su značajno veća u toj skupini do 96. tjedna.
Decreases in BMD of spine and changes in bone biomarkers from baseline were significantly greater in the tenofovir disoproxil fumarate treatment group at 144 weeks.
Smanjenja BMD-a kralježnice i promjene koštanih biomarkera od početne vrijednosti bila su u 144. tjednu značajno veća u skupini koja je liječena tenofovirdizoproksilfumaratom.
Decreases in BMD of spine and changes in bone biomarkers from baseline were significantly greater in the tenofovir disoproxil fumarate treatment group at 144 weeks.
Smanjenja BMD-a kralježnice i promjene koštanih biomarkera od početne vrijednosti bili su značajno veći u skupini liječenoj tenofovirdizoproksilfumaratom u 144. tjednu.
Decreases in BMD of spine and changes in bone biomarkers from baseline were significantly greater in the tenofovir disoproxil fumarate treatment group at 144 weeks.
Smanjenja BMD-a kralježnice i promjene koštanih biomarkera od početne vrijednosti, bile su u 144 tjedna značajno veće u skupini liječenoj tenofovirdizoproksilfumaratom.
Decreases in BMD of spine and changes in bone biomarkers from baseline were significantly greater in the tenofovir disoproxil fumarate treatment group at 144 weeks.
Sniženja BMD-a kralježnice i promjene vrijednosti koštanih bioloških biljega u odnosu na početne bila su značajno veća u terapijskoj skupini koja je primala tenofovirdizoproksilfumarat u 144. tjednu.
Decreases in BMD of spine and changes in bone biomarkers from baseline were significantly greater in the tenofovir disoproxil treatment group at 144 weeks.
Smanjenja mineralne gustoće kostiju kralježnice i promjene koštanih bioloških biljega od početne vrijednosti bile su u 144. tjednu značajno veće u skupini liječenoj tenofovirdizoproksilom.
Decreases in bone mineral density of spine and changes in bone biomarkers from baseline were significantly greater in the tenofovir disoproxil fumarate treatment group at 144 weeks.
Smanjenje mineralne gustoće kosti kralježnice i promjene koštanih biomarkera od početne vrijednosti bile su pri 144 tjedna značajno veće u skupini liječenoj tenofovirdizoproksil fumaratom.
Decreases in diastolic and systolic pressure and heart rate were noted in the minipig, and a tendency to a hypotensive effect was discerned in the monkey.
Smanjenje dijastoličkog i sistoličkog tlaka i broja otkucaja srca uočeno je kod patuljastih svinja, kao i sklonost hipotenzivnom učinku u majmuna.
Decreases in diastolic and systolic pressure and heart rate were noted in the minipig, and a tendency to a hypotensive effect was discerned in the monkey.
Smanjenje dijastoličkog i sistoličkog tlaka i broja otkucaja srca uočeno je u patuljastih svinja, kao i sklonost hipotenzivnom učinku u majmuna.
Decreases in haemoglobin, neutrophils and platelets may require dose reduction or permanent discontinuation from treatment (see Table 3 and Table 7).
Sniženje vrijednosti hemoglobina, neutrofila i trombocita može zahtijevati smanjenje doze ili Trajan prekid liječenja (vidjeti tablicu 3 i tablicu 7).
Decreases in LVEF in subjects who had post-baseline and follow up LVEF measurement were detected in 11 % (15/140) in the pazopanib arm compared with 3 % (1/39) in the placebo arm.
Smanjenje LVEF, u ispitanika kojima je LVEF mjeren nakon početka ispitivanja te u periodu praćenja, zabilježeno je u 11% (15/140) u skupini bolesnika na pazopanibu u usporedbi s 3% (1/39) onih u placebo skupini.
Decreases in oestrogen levels that occur after the menopause lead to vulvar and vaginal atrophy (VVA), characterised by decreased maturation of vaginal epithelial cells, a progressive decrease in the vascularity of the vaginal tissues, and decreased lubrication.
Pad razine estrogena koji se događa nakon menopauze dovodi do vulvarne i vaginalne atrofije (VVA), karakterizirane smanjenim sazrijevanjem stanica vaginalnog epitela, progresivnim smanjenjem vaskularnosti vaginalnih tkiva i smanjenom lubrikacijom.
decreases in phosphate in the blood
smanjenje fosfata u krvi
decreases in phosphate in the blood increased creatine kinase
manjenu razinu fosfata u krvi povišena kreatin kinaza
decreases in phosphate in the blood, increased creatine kinase.
manjenja količine fosfata u krvi povišene razine kreatin kinaze
Decreases in phosphate levels in the blood
nižene razine fosfata u krvi
decreases in phosphate levels in the blood increased levels of creatine kinase in the blood that may result in muscle pain and weakness
manjene razine fosfata u krvi povećane razine kreatin kinaze u krvi koje mogu dovesti do bolova u mišićima i slabosti
decreases in potassium in the blood
manjenu razinu kalija u krvi
Decreases in potassium in the blood
niženje kalija u krvi
decreases in potassium in the blood,
manjenu razinu kalija u krvi
Decreases in serum potassium and sodium
Manje često: Smanjenje koncentracije kalija i natrija u serumu
decreases in the amount of white blood cells (these will show up in blood tests)
manjenje broja bijelih krvnih stanica (to će se pojaviti u krvnim testovima)
decreases in the number of red blood cells (that may cause fatigue, shortness of breath, dizziness), decrease in neutrophils (that make you more susceptible to different infections),
manjenje broja crvenih krvnih stanica (koje može uzrokovati umor, nedostatak zraka, omaglicu), smanjenje broja neutrofila (zbog čega možete biti osjetljiviji na razne infekcije),
decreases in the number of red blood cells (that may cause fatigue, shortness of breath, dizziness), decrease in neutrophils (that make you more susceptible to different infections).
manjenje broja crvenih krvnih stanica (to može uzrokovati umor, nedostatak zraka, omaglicu), smanjenje broja neutrofila (zbog čega možete biti osjetljiviji na razne infekcije),
decreases in the number of red blood cells (that may cause fatigue, shortness of breath, dizziness), decrease in neutrophils(that make you more susceptible to different infections),
manjenje broja crvenih krvnih stanica (to može uzrokovati umor, nedostatak daha, omaglicu), smanjenje broja neutrofila (zbog čega možete biti osjetljiviji na razne infekcije),
decreases in the number of red or white blood cells (anaemia, neutropenia)*
manjenje broja crvenih ili bijelih krvnih stanica (anemija, neutropenija)
decreases in the number of white blood cells or red blood cells (seen in tests)
manjenje broja bijelih ili crvenih krvnih stanica (vidi se iz nalaza pretraga)
decreases in the number of white blood cells or red blood cells (seen in tests)
manjenje broja bijelih krvnih stanica ili crvenih krvnih stanica (uočeno u nalazima)
decreases in the number of white blood cells or red blood cells (seen in tests),
manjeni broj bijelih ili crvenih krvnih stanica (otkriva se krvnim pretragama)
Decreases in total IgG, IgA, or IgM levels below normal were observed in the range of 4 to 11% patients in the MCD trial (Study 1).
Smanjenja razina ukupnih IgG, IgA ili IgM ispod normalnih, opažena su u rasponu od 4 do 11% bolesnika u MCD ispitivanju (Ispitivanje 1).
Decreases in white blood cell
manjenje broja leukocita
Decreases in white blood cell counts
manjenje broja leukocita
Decreases in white blood cell counts of <3.0 x 109/L were observed in 7% of patients receiving Plegridy and in 1% receiving placebo.
Smanjenje broja bijelih krvnih stanica od <3,0 x 109/l opažena su u 7% bolesnika koji su primali Plegridy i u 1% koji su primali placebo.
Decreasing hearing (ringing in the ears is a potential warning sign of hearing loss), noises (such as hissing) in the ears (common).
Slabljenje sluha (zvonjava u ušima je potencijalni znak upozorenja za gubitak sluha), zvukovi (poput pištanja) u ušima (često).
Dedicated fertility studies have not been conducted with trastuzumab emtansine.
Nisu provedena posebna ispitivanja učinka trastuzumab emtanzina na plodnost.
Dedicated nonclinical studies to evaluate the carcinogenicity of vismodegib have not been performed.
Nisu provedena posebna neklinička ispitivanja kojima bi se procijenila kancerogenost vismodegiba.